Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Public ClinicalTrials.gov record NCT00090194. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients
Study identification
- NCT ID
- NCT00090194
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Interventions
- Immune Globulin Intravenous (Human), 10% Biological
Biological
Eligibility (public fields only)
- Age range
- 1 Year to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2003
- Primary completion
- Not listed
- Completion
- Feb 29, 2004
- Last update posted
- Jan 10, 2017
2003 – 2004
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital of Alabama | Birmingham | Alabama | 35233 | — |
| Banner Good Samaritan Regional Medical Center | Phoenix | Arizona | 85006 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| California Pacific Medical Center | San Francisco | California | 94115 | — |
| University of San Francisco | San Francisco | California | 94117 | — |
| Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Indiana University Medical Center | Indianapolis | Indiana | 46202 | — |
| University of Massachusetts Medical Center | Worcester | Massachusetts | 01655 | — |
| University of Michigan Hospitals | Ann Arbor | Michigan | 48109 | — |
| University of Cincinnati | Cincinnati | Ohio | 45219 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37235 | — |
| University of Texas Medical Branch | Galveston | Texas | 77555 | — |
| Swedish Medical Center | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00090194, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 10, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00090194 live on ClinicalTrials.gov.